{"commentary":{"count":32,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":14,"youtube":9,"podcast":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07491445\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RASolute 303","nct_id":"NCT07491445","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rasolute-303-nct07491445. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"RASolute 303","arms":[{"description":"study drug","label":"Arm A: daraxonrasib","type":"EXPERIMENTAL"},{"description":"study drug in combination with chemotherapy","label":"Arm B: daraxonrasib + gemcitabine and nab-paclitaxel","type":"EXPERIMENTAL"},{"description":"SOC chemotherapy","label":"Arm C: gemcitabine and nab-paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-03","type":"ESTIMATED"},"conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma"],"enrollment":{"count":900,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"daraxonrasib","type":"DRUG"},{"name":"gemcitabine","type":"DRUG"},{"name":"nab-paclitaxel","type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"Revolution Medicines, Inc.","official_title":"RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS)","timeFrame":"Up to approximately 2 years"},{"measure":"Overall survival (OS)","timeFrame":"Up to approximately 2 years"}],"references":[],"start_date":{"date":"2026-03-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT07491445"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rasolute-303-nct07491445"}